Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (August 2018)
21 slides from Neurotech International's investor presentation, Aug 13, 2018
Slide 1: Bridging to a better life – Investor Presentation
For personal use only Bridging to a better life Investor Presentation Neurotech International Limited (ASX: NTI) | 13 August 2018
Slide 2: Disclaimer
Disclaimer For personal use only This presentation contains forward looking statements that involve risks & uncertainties. These forward looking statements are not guarantees of Neurotech’s future performance & involved a number of risks & uncertainties that may cause actual results to differ materi
Slide 3: Neurotech overview
Neurotech overview For personal use only ✓ Medical device company, focussed on the development & commercialisation of regulated medical solutions for diagnosis & treatment of neurological disorders ✓ Flagship device Mente Autism provides home-based neurofeedback therapy to children on the autism spe
Slide 4: Capital structure & key shareholders
Capital structure & key shareholders For personal use only Market Capitalisation & Enterprise Value Share Price / Volume History (A$; millions) Units Value ASX Closing Price (A$) Volume (m) 0.40 12.0 Ordinary shares m 109.0 0.35 10.0 Options m 10.9 0.30 Fully diluted capital1 m 119.9 8.0 0.25 Share
Slide 5: Highly experienced board
Highly experienced board For personal use only Peter O’Connor • Deep experience in global funds management, asset allocation & manager selection advisory Chairman (Non-Exec) • Held senior public company directorships (UK, Canada & Australia) MA, Barrister-at Law • Non-executive director of Northern
Slide 6: Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD) For personal use only • ASD (or autism) is a lifelong development condition Standard treatments include1 • One in 68 children have some form of ASD Behaviour & • There is no cure, so the goal of every treatment is to: Educational Medication communication Neurofeedback
Slide 7: Market positioning & opportunity
Market positioning & opportunity For personal use only Medical Neurotechnology Clinical Grade Home Care • Understanding & influencing the brain & • Health care moving toward precision-based nervous system personal care • ‘Next frontier’ in medical science • Particularly for lifestyle disorders & chr
Slide 8: First target consumer market – Europe
First target consumer market – Europe For personal use only United Kingdom Population: 65 million Target market: 32,500 Germany, Austria & Switzerland Populations: 98 million Target market: 49,000 Italy Population: 61 million Prevalence of autism: 1% 3-12 years target segment: 10% of autistic suffer
Slide 9: Mente Autism – how it works
Mente Autism – how it works • Autism has been linked to For personal use only an excess of low-frequency Theta & Delta waves, &/or an excess of high frequency Beta waves, which have been shown to affect the way information is processed. • Using clinical-quality 4- channel EEG device, Mente Autism is
Slide 10: Improved Mente Autism device now available
Improved Mente Autism device now available For personal use only Complete Mente Autism Kit What’s new in the improved Mente? ✓ wi-fi connectivity ✓ synchronisation ✓ usability ✓ firmware ✓ application Manu. Price €280 (ex. VAT) RRP €1,700 (ex. VAT) RRP €1,850 with tablet (ex. VAT) Comprising headban
Slide 11: US clinical trial
US clinical trial For personal use only • Carried out by Florida’s Carrick Institute, the trial was a randomized-controlled, double blind investigation that compared Mente Autism with a control (or sham) device over 12 weeks • Mente Autism was found to significantly improve cognitive, postural & beh
Slide 12: Multi-site studies
Multi-site studies For personal use only Type Lead investigator Scope No. of subjects Impact Timeline US Clinical Validate effectiveness of Prof. Frederick 34 (completed Trial United States Mente Autism; can support Completed Carrick trial) (completed) submission to US-FDA Continue to build awarenes
Slide 13: Certifications
Certifications The Mente Autism device already has European CE Marking & TGA Registration, thus enabling sales in For personal use only Europe, Middle East & Australia. The Company will seek to also obtain US FDA clearance for the device. Current Certifications & Registrations FDA Submission Process
Slide 14: Distribution network
Distribution network For personal use only • Marketing & distribution • Marketing & distribution partner in Australia partner in Greece & Cyprus Marketing & • Marketing & distribution distribution partner in partner in Austria Italy • Marketing & distribution • Marketing & distribution partner in Ge
Slide 15: German market entry strategy
German market entry strategy For personal use only • Neurotech appointed German distribution partner VDT Psychologie Medizinvertrieb – April 2017 • Three-step approach to creating structure to develop a successful market in Germany: 1. Appoint distribution partner (complete) 2. Build medical profess
Slide 16: Italian neurofeedback centres & endorsements
Italian neurofeedback centres & endorsements For personal use only • Opening of first neurofeedback centres in Italy – Orvieto, Canosa di Puglia & Caserta • Plans to open neurofeedback centre in Sardegna • Three endorsement videos by medical professionals, available on the Mente website • Increasing
Slide 17: Updated Mente Autism website
Updated Mente Autism website For personal use only ✓ Fresher look with new imagery ✓ Direct ‘calls to action’ ✓ Pre-sales assessment to gauge eligibility to use Mente Autism ✓ Usability improvements www.mentetech.com 17
Slide 18: Marketing activities & spreading awareness
Marketing activities & spreading awareness For personal use only ✓ Direct mailing to contacts ✓ Outreach to media & press contacts ✓ Social media activity to target potential customers ✓ Autism group events ✓ Dedicated Mente pages on distributor websites 18
Slide 19: Key achievements & next milestones
Key achievements & next milestones For personal use only Latest Achievements Looking Forward… ✓ June 2018: Endorsement videos from Italian medical August 2018: Initiation of reimbursement preparation professionals process in Australia ✓ June 2018: New testimonials from Italian parents September
Slide 20: Contact Details
Contact Details For personal use only Company Investor / Media Relations Wolfgang Storf, Chief Executive Officer Matthew Wright wolfgang.storf@aatrl.com matt@nwrcommunications.com.au Neurotech International Ltd NWR Communications Level 14, 191 St Georges Terrace Level 6, 350 Collins St Perth Western
Slide 21: For personal use only
For personal use only www.neurotechinternational.com www.mentetech.com
Neurotech International — Investor Presentation (August 2018) on 6ix